American Society of Hirudotherapy

Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery

Research article published in The Journal of biological chemistry (2004)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSalivary PharmacologyCarter et al. · The Journal of biological chemistry, 2004

Abstract

Thrombin is the ultimate protease of the blood clotting cascade and plays a major role in its own regulation. The ability of thrombin to exhibit both pro- and anti-coagulant properties has spawned efforts to turn thrombin into an anticoagulant for therapeutic purposes. This quest culminated in the identification of the E217K variant through scanning and saturation mutagenesis. The antithrombotic properties of E217K thrombin are derived from its inability to convert fibrinogen to a fibrin clot while maintaining its thrombomodulin-dependent ability to activate the anticoagulant protein C pathway. Here we describe the 2.5-A crystal structure of human E217K thrombin, which displays a dramatic restructuring of the geometry of the active site. Of particular interest is the repositioning of Glu-192, which hydrogen bonds to the catalytic Ser-195 and which results in the complete occlusion of the active site and the destruction of the oxyanion hole. Substrate binding pockets are further blocked by residues previously implicated in thrombin allostery. We have concluded that the E217K mutation causes the allosteric inactivation of thrombin by destabilizing the Na(+) binding site and that the structure thus may represent the Na(+)-free, catalytically inert "slow" form.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAllosteric SiteBinding SitesCatalysisCrystallography, X-RayHumansHydrogen BondingModels, MolecularMutagenesis, Site-DirectedProtein BindingProtein ConformationSodiumThrombin

Summary

The 2.5 A crystal structure of anticoagulant thrombin variant E217K reveals active-site occlusion with oxyanion-hole destruction, indicating the mutation allosterically inactivates thrombin by destabilizing Na+ binding and may represent the Na+-free, catalytically inert 'slow' form.

Context

This study determined the 2.5 Å crystal structure of the anticoagulant thrombin variant E217K, revealing dramatic active-site restructuring including Glu-192 repositioning that hydrogen bonds to catalytic Ser-195, resulting in complete occlusion of the active site and destruction of the oxyanion hole. The authors conclude that the E217K mutation causes allosteric inactivation of thrombin by destabilizing the Na+ binding site and that the structure may represent the Na+-free, catalytically inert 'slow' form. The work provides structural insight into thrombin allostery relevant to anticoagulant design. CAVEAT: No hirudin, leech-derived compounds, or hirudotherapy are mentioned in the abstract.

Citation

Reference (Vancouver style)

Carter WJ, Myles T, Gibbs CS, Leung LL, Huntington JA. Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. J Biol Chem. 2004;279(25):26387-26394. doi:10.1074/jbc.M402364200. PMID: 15075325

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.